MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive: To decipher further the mechanism of action of this compound in CML cells, we analyzed the effect of a panel of pharmacological agents known to inhibit the main cellular signaling pathways including p38MAPK, JNK, ERK1/2, PI3K, mTOR, PKA, PKC and the caspase cascade.